Purdue Pharma, the makers of OxyContin®, have begun to distribute a new formulation of their drug as of mid August 2010. The drug itself remains intact and has not changed, however two distinct changes have been made:
- The new indicia for all of the strengths of OxyContin® now have the letters “OP” instead of the previous version which had “OC”. The other side of the tablet will remain the same with the milligram strength listed. The colors of the pills will also remain the same, but the 80mg. tablets are slightly larger.
- All strengths of the pills have been manufactured in a way to make it harder to break down the OxyContin® for injection, snorting, or chewing.
The photos shown in the downloadable document show the different strengths in actual size, along with their corresponding wholesale bottles. Since this has just been introduced into the market, there is no way currently to tell whether the new formulation will be successful or not, but the vast majority, if not all, of the old formulation OxyContin® should be gone by the end of 2010 or earlier.
Download information here
Article on the use and misuse of buprenorphrine in the management of opioid addiction.
"This study examines a new approach that focuses on reducing abusability through the use of abuse-resistant drug designs."
NADDI member Arthur Thexton, from the Wisconsin Department of Regulation and Licensing, has compiled a list of doctor shopping statutes for all 50 states.
This article, written by NADDI President John Burke, discusses the pervasiveness of prescription drug diversion.
Written by Kim New - Article discussing the basic elements of an effective diversion prevention, detection and response program.
Article written by NADDI member James Rawson on medical practice online
An analysis of four unique indicators published by John J. Coleman, Ph.D.
The U.S. Department Of Justice's National Drug Intelligence Center and Drug Enforcement Administration Office of Diversion Control released the 2009 National Prescription Drug Threat Assessment in May.
This worksheet may be used for tabulating violations and assessing drug "administration" patterns when conducting investigations of nurse dirverters within health care facilities. Submitted by David N. Register, Narcotic Investigator, through RxNews.
This affidavit is a valuable tool for Rx Investigations. Submitted by Scott Darlow (HCSO) through RxNews.
There is a "Pharmacist's Manual" on the DEA diversion website which is an official publication of DEA. Submitted by Arthur Thexton through RxNews.
Article about how insurance fraud finances the theft and abuse of addictive prescription drugs
Guidelines on proper disposal of unused or unwanted prescription drugs.